Pressemitteilung BoxID: 787661 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • Ansprechpartner
  • Wolfgang Güssgen
  • +49 (89) 700763-73

Chairman of the Management Board Enno Spillner will not extend his current term of office, but will leave the Company after a transitional period ending 30 June 2016

(PresseBox) (Planegg-Martinsried, ) The Chairman of the Management Board of 4SC AG (4SC, FSE Prime Standard: VSE), Enno Spillner, informed 4SC's Supervisory Board today that he will not accept the recently received offer to extend his current term of office ending 31 March 2016. However, Enno Spillner will continue to be at the Company's disposal as Chairman of the Management Board for a transitional period ending 30 June 2016.

4SC's Supervisory Board thanks Enno Spillner for more than 10 years of valuable Management Board service and his sustained engagement for the Company.

Information and Explanation of the Issuer to this News:

Dr Clemens Doppler, Chairman of the Supervisory Board of 4SC, comments: 'Enno Spillner's decision is to my very regret, and in the name of the entire Supervisory Board I would like to thank him explicitly for his valuable contributions to the Company and his sustained engagement. Especially over the last three years in which he has been responsible in a CEO / CFO double role, his activities have been instrumental to the advancement of the Company, especially his achievements related to the strategic repositioning and to a successful capital increase. We wish Enno Spillner all the best for his future.'

Forward-looking information

This ad hoc release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this ad hoc release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.



4SC ( is a biotechnology company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 67 employees (headcount) or 58 full-time equivalents (FTEs) at 31 December 2015. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.